Teva teams up with Cancer Research UK development company
This article was originally published in Scrip
Executive Summary
Teva Pharmaceuticals will collaborate with a technology and development arm of charity Cancer Research UK, in order to develop first-in-class drugs modulating DNA damage and repair response (DDR) processes in cancer cells.